Melissa Lipari

Melissa Lipari

Auto-generated profile, based on publicly available information

Melissa Lipari

Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
IMInsaf Mohammad
Insaf Mohammad
HBHelen D. Berlie
Helen D. Berlie
MLMelissa Lipari
Melissa Lipari
AMAmber Lanae Martirosov
Amber Lanae Martirosov
ADAndrea A. Duong
Andrea A. Duong
CGCandice L. Garwood
Candice L. Garwood
The coronavirus disease (COVID‐19) has created a variety of challenges for health care professionals, including ambulatory care clinical pharmacists. High‐quality remote and minimal‐contact care has become a necessity. Ambulatory care clinical pharmacists around the nation have adjusted their practice. In many cases, this included implementation of telehealth programs for comprehensive medication management. The redesign of ambulatory care Advanced Pharmacy Practice Experiences (APPE) also required quick adaptation. In this paper, we describe the clinical practice and experiential education challenges encountered by an ambulatory care clinical pharmacist workgroup in a COVID‐19 “hotspot,” with an emphasis on solutions and guidance. We discuss how to adapt ambulatory care clinical pharmacy practices including methods of minimal‐contact care, reimbursement opportunities, tracking outcomes, and restructuring ambulatory care APPE. As ambulatory care clinical pharmacists continue to expand the services they provide in response to COVID‐19, we also describe opportunities to promote pharmacists as providers during times of pandemic and into the future.

1 February 2021 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
CGChristopher Giuliano
Christopher Giuliano
AMAmber Lanae Martirosov
Amber Lanae Martirosov
MLMelissa Lipari
Melissa Lipari
SWSheila Wilhelm
Sheila Wilhelm
FSFrancine Salinitri
Francine Salinitri
JBJuliann Binienda
Juliann Binienda

22 January 2022 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
MLMelissa Lipari
Melissa Lipari
SWSheila M. Wilhelm
Sheila M. Wilhelm
CGChristopher Giuliano
Christopher Giuliano
AMAmber Lanae Martirosov
Amber Lanae Martirosov
FSFrancine D. Salinitri
Francine D. Salinitri

19 September 2022 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
LLLauren Lim
Lauren Lim
MLMelissa Lipari
Melissa Lipari
PKPramodini Kale-Pradhan
Pramodini Kale-Pradhan
Objective: To review the pharmacology, efficacy, and safety of intranasal olopatadine hydrochloride-mometasone furoate (OM) combination in the treatment of seasonal allergic rhinitis (SAR). Data sources: The PubMed database and ClinicalTrials.gov were searched using the following terms: mometasone + olopatadine, GSP301, mometasone furoate, and olopatadine hydrochloride. Study Selection and Data Extraction: Articles published in English between January 1987 and August 2022 related to pharmacology, safety, and clinical trials were assessed. Data Synthesis: In 2 phase II clinical trials, twice-daily (BID) and once-daily (QDay) intranasal OM demonstrated significant improvements in reflective total nasal symptom score (rTNSS) (BID P < 0.001 and QDay P < 0.001) and instantaneous total nasal symptom score (iTNSS) (BID P < 0.001 and P < 0.0001; QDay P < 0.001 and P < 0.0001). In 2 phase III clinical trials, BID OM showed significant improvements in rTNSS vs. placebo ( P < 0.001), olopatadine monotherapy ( P = 0.03 and P = 0.003), and mometasone monotherapy ( P = 0.02 and P = 0.059). Relevance to Patient Care and Clinical Practice: OM is indicated for treatment of SAR symptoms. Caution with use must be considered for certain high-risk patients, existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Due to its quick and sustained onset of action, OM may be an ideal agent for initial treatment of moderate-severe SAR for patients 12 years and older. Conclusion: OM significantly improves SAR symptoms and is a viable treatment option in short-term SAR.

10 May 2022 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
JFJacqueline Feist
Jacqueline Feist
MLMelissa Lipari
Melissa Lipari
PKPramodini Kale-Pradhan
Pramodini Kale-Pradhan
Objective: To review the pharmacology, efficacy, and safety of subcutaneous tezepelumab in the treatment of severe uncontrolled asthma. Data Sources: The PubMed database and ClinicalTrials.gov were searched using the following terms: tezepelumab, Tezspire, AMG157, and MEDI9929. Study Selection and Data Extraction: Articles published in English between January 2000 and March 2022 related to pharmacology, safety, and clinical trials were assessed. Data Synthesis: In a phase 2 trial, tezepelumab at low, medium, and high doses reduced the annualized asthma exacerbation rate by 62%, 71%, and 66%, respectively, when compared with placebo ( P < 0.001). In addition to significant reduction of asthma exacerbation rate in the overall treatment population, a phase 3 trial showed significant reduction of asthma exacerbation across all subgroups analyzed regardless of serum eosinophil count (EOS), fractionated exhaled nitric oxide (FeNO) level, or allergic status as determined by IgE sensitivity. Relevance to Patient Care and Clinical Practice: Tezepelumab is indicated to treat nonallergic and noneosinophilic severe uncontrolled asthma phenotypes in addition to type 2 inflammatory asthma. When selecting the most appropriate biologic agent, consider the risks, benefits, and costs. There is a paucity of data on the efficacy of tezepelumab in patients with comorbid conditions. In the case of a patient presenting with uncontrolled severe asthma with such comorbid conditions, it may be prudent to consider a biologic therapy that can target both. Conclusion: Tezepelumab has shown clinical utility in severe uncontrolled asthma regardless of phenotype, fulfilling the need for treatment options in individuals with severe, uncontrolled, noneosinophilic, and nonallergic asthma.

24 September 2020 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
JGJamie George
Jamie George
MGMichelle Ganoff
Michelle Ganoff
MLMelissa Lipari
Melissa Lipari
Background: Recent literature and guidelines support treatment of severe acute exacerbation of COPD (AECOPD) with prednisone 40 mg (or equivalent) for 5 days. Objective: The purpose of this study was to determine whether systemic corticosteroids were being prescribed at the appropriate dose and duration in the treatment of severe AECOPD at a large academic medical institution. Methods: This was a single-center, retrospective, observational study conducted to evaluate corticosteroid prescribing patterns for adults admitted for severe AECOPD from March to May 2019 at a large academic medical institution. Appropriate therapy was defined as: prednisone 40 mg (or equivalent) for 5 days. The primary outcome was to determine the frequency of appropriate dose and duration. The secondary outcomes were to identify the frequency of appropriate dose or duration, compare the prevalence of adverse effects, such as new/worsening hyperglycemia or hypertension, and compare 30- and 90-day readmission rates. Results: Of the 190 patients included, 16 (8.4%) had an appropriate duration and 8 (4.2%) an appropriate dose. Only 4 patients (2.1%) had both appropriate corticosteroid dose and duration. New/worsening hyperglycemia occurred in 96 (50.5%), and hypertension developed in 13 (6.8%). Thirty-day readmission occurred in 46 (24.2%) and 90-day readmission in 78 (41.1%). These were more likely in those without appropriate dose and duration. Conclusion: Systemic corticosteroids for the treatment of severe AECOPD are not prescribed in accordance with evidence-based recommendations at this institution. This might result in a greater incidence of adverse effects and readmissions.